GlassScriptPhysician profile
In C Shin
NPI 1245215656
$11,958.79
in general payments reported to CMS, 2019-2025
28 companies · $2,145 in 2025
The $2,145 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,796 · 2020: $2,240 · 2021: $951 · 2022: $1,268 · 2023: $1,273 · 2024: $1,285 · 2025: $2,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,702.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $3,243.73 | 2019-2022 | |
| Abbvie INC. | $1,628.12 | 2022-2025 | Durysta, Xen Glaucoma Treatment System |
| Johnson & Johnson Surgical Vision, INC. | $1,118.79 | 2019-2025 | Tecnis Simplicity, Amo Phaco Needle, Tecnis Iol |
| Alcon Vision LLC | $1,078.41 | 2019-2025 | Rocklatan, Clareon, Hydrus Microstent |
| Allergan, INC. | $830.07 | 2019-2022 | |
| Glaukos Corporation | $745.30 | 2019-2025 | Idosetr, Idose, Photrexa Viscous and Photrexa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $691.45 | 2019-2021 | |
| Sight Sciences, INC. | $357.06 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Tarsus Pharmaceuticals, INC. | $295.76 | 2024-2025 | Xdemvy |
| Ocular Therapeutix, INC. | $267.53 | 2019-2023 | Dextenza |
| Bausch & Lomb Americas INC. | $234.98 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| New World Medical,INC. | $226.54 | 2022-2025 | Clearpath, Streamline, Kahook Dual Blade |
| Eyevance Pharmaceuticals LLC | $222.91 | 2020-2023 | Flarex |
| Sun Pharmaceutical Industries INC. | $151.78 | 2019-2025 | |
| Dompe US, INC. | $150.53 | 2022-2025 | Oxervate |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $136.59 | 2019-2021 | |
| Beaver-Visitec International, INC. | $108.22 | 2022 | |
| Rxsight INC | $86.86 | 2023-2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Novartis Pharmaceuticals Corporation | $65.35 | 2019-2023 | |
| Biotissue Holdings INC. | $60.32 | 2022-2025 | |
| Oyster Point Pharma, INC. | $59.99 | 2023 | Tyrvaya |
| Thea Pharma INC. | $40.12 | 2022-2023 | |
| Shire North American Group INC | $39.96 | 2019 | |
| Iridex Corporation | $38.17 | 2021-2022 | |
| Nova Eye, INC. | $24.88 | 2024 | |
| Ani Pharmaceuticals, INC. | $23.04 | 2025 | Purified Cortrophin Gel |
| Aerie Pharmaceuticals, INC. | $16.63 | 2019 | |
| Omeros Corporation | $15.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw In Shin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.